Dr. Xenia Boergen specialises in intellectual property law and regulatory law with a focus on the life sciences sector/pharma/biotechnology.
In patent litigation, Xenia has broad experience in advising on both international and national patent litigation. In regulatory law, she has advised on a broad range of complex issues, including biopharmaceuticals, especially advanced therapy medicinal products.
After completing a Bachelor of Science in Biochemistry at Queen Mary and Westfield College, University of London, and a Master of Science/Diploma in Biotechnology at Imperial College of Science, Technology and Medicine, University of London, Xenia worked as a researcher in molecular biology/genetics at Ludwig Maximilian University in Munich.
Later on she studied law at Humboldt University in Berlin, followed by a PhD on “Constitutional evaluation of therapeutic and reproductive cloning and cell research”.
After working as a lawyer at a leading German IP firm, Xenia joined the law department of Roche Pharma AG. Before opening her own offices in Berlin, she was the head of pharmaceuticals law and innovations and the corporate patent and legal department at leading German biotech Miltenyi Biotec GmbH and at an international law firm.
Xenia is working for the BPI (Bundesverband der Pharmazeutischen Industrie e.V., German Pharmaceutical Industry Association) and BIO Deutschland, the Biotechnology Association in Germany.